9 results about "Pharmacogenomics" patented technology

The invention discloses a pharmacogenomics report generation method and device, a medium and a product, and relates to the field. The method comprises the following steps: in response to the completion of a drug genome experiment of a first object, obtaining experimental result data of the drug genome experiment, and determining experimental result interpretation data based on a first drug gene association database; inputting the experimental result interpretation data, the object attribute information corresponding to the first object, the medical record information and the first medicine information into a pre-trained medication risk assessment model to obtain a medication risk assessment result of the first object; and generating a pharmacogenomics report of the first object based on the medication risk assessment result, the experimental result interpretation data, the object attribute information, the medical record information and the first drug information. According to the technical scheme of the invention, the problems of high threshold and low efficiency of the existing pharmacogenomics report generation are solved, the pharmacogenomics report can be automatically generated, the accuracy of the report content is improved, and the report generation cost is reduced.

The present invention relates to the field of pharmacogenomics, which applies one or more genomic biomarkers and the related diagnostic methods, devices, reagents, systems, and kits, for predicting varied individual responses such as, for example, efficacy or adverse effect, to therapeutic agents, e.g., inhibitors of certain neurotransmitter transporters such as liafensine.

The invention relates to the field of virology and pharmacogenomics, in particular to a molecular marker combination and application thereof in preparation of a bavirin drug resistance monitoring kit. The molecular marker combination is a single nucleotide polymorphism located at the 603rd nucleotide site of the reference sequence and a single nucleotide polymorphism located at the 913th nucleotide site of the reference sequence of the RSVF gene. And the 603rd nucleotide is changed from adenine to cytosine, so that the sensitivity of the virus to ribavirin is changed. And the 913th nucleotide is changed from cytosine to adenine, so that the sensitivity of the virus to ribavirin is changed.

A health analysis method has the steps of obtaining test data of a patient sample, cleaning the test data by removing data items independent of the health analysis, obtaining statistics of the cleaned test data, and determining a health analysis result based on the obtained statistics of the cleaned test data and statistics of the health data. Analysis results of one or more genes and / or species of a patient sample are obtained using one or more artificial intelligence (AI) methods.

The present invention relates to a clinical decision support system comprising a processing unit in communication with a memory. The processing unit is configured to receive and process clinical data associated with a patient, which comprises medical records, biometric or physiological data, and / or currently prescribed medication information. The system computes personalized target lipid profile ranges based on the clinical data and medical guidelines stored in the memory. Preferably, the system receives pharmacogenetic analysis data and measured lipid profile values from patient blood tests. The processing unit compares the measured lipid values with the personalized target ranges and, if deviations are found, computes a list of potential medication treatments. This list is sorted based on the estimated effects of each treatment on the lipid profile values, the different between measured and objective lipid profile values, on the clinical data and / or on the pharmacogenetic analysis. The system further outputs data related to the personalized lipid ranges, the comparison of measured values, and / or the suggested medication treatments.

The invention discloses a test method of reaction of EPHX1 genotype based COPD to NAC. The test method comprises the following steps: extracting a DNA by a phenol / chloroform method and sequencing, dividing COPD patients into slow and very slow gene activity group and a quick and normal gene activity group according to EPHX1 gene polymorphism, giving 600 mg Bid of NAC for 1 year to both groups, performing baseline measurement of pulmonary function parameters, completing SGRQ and 6MWT, measuring FVC and FEV1 at a follow-up day every 12 weeks, completingSGRQ and 6MWT in 24 and 48 weeks, and recording the number of acute exacerbationof COPD in one year. The data were statistically analyzed with SPSS. The results show that NAC is effective in the treatment of slow and very slow EPHX1 gene activityCOPD patients. The test method provided by the invention provides a solid basis for demonstrating the effect and mechanism of NAC based on pharmacogenomics in the individualized treatment of COPD.

This invention relates to the fields of biotechnology and pharmacogenomics detection, and discloses a kit and application for gene detection of drugs used in general anesthesia. The kit contains a primer set for detecting genetic polymorphic loci related to commonly used perioperative anesthetic, analgesic, and muscle relaxant drugs. The primer set includes multiplex PCR amplification primers and single-base extension primers. The kit also includes multiplex PCR amplification reaction solution, SAP reaction solution, SAP enzyme, extension buffer, single-base extension termination mixture, extension reaction enzyme, desalting purification resin, standards, calibrators, deionized water, and instructions for use. This invention uses matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF) to genotype SNP loci, obtaining genotype results for 103 genetic polymorphic loci in a single test. This allows for the prediction of individual differences in drug metabolism, drug efficacy, and adverse reaction risk, providing a basis for personalized medication in general anesthesia.